High-yield method and kit for preparing mRNA by reducing or inhibiting double-stranded RNA formation during in vitro transcription
By using water-insoluble negatively charged solid phase media in vitro transcription, the problem of dsRNA production is solved, the yield and stability of mRNA is improved, operation is simplified and cost is reduced, and efficient mRNA preparation is achieved.
Patent Information
- Application Number
- PCT/CN2024/091989
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art is difficult to efficiently and economically reduce the production of double-stranded ribonucleic acid (dsRNA) during in vitro transcription, resulting in low mRNA yield, poor stability and complex operation. Common methods can contaminate the transcription system or affect the activity of T7 polymerase.
During in vitro transcription, negatively charged solid phase medium is added to reduce dsRNA production through interface regulation and improve mRNA yield and stability, so that solid phase medium is easy to separate and reuse.
It has achieved efficient reduction of dsRNA production in in vitro transcription, improved mRNA yield and stability, simplified operation, reduced costs, and improved mRNA transfection efficiency and safety of immune factor expression.
Smart Images

Figure CN2024091989_14112024_PF_FP_ABST
Abstract
Description
A high-yield mRNA preparation method and kit that reduces or inhibits the formation of double-stranded ribonucleic acid during in vitro transcription Technical Field
[0001] The present invention relates to the technical field of in vitro transcription and synthesis of mRNA and separation and purification of ribonucleic acid, and in particular to a high-yield mRNA preparation method and a kit for reducing or inhibiting the formation of double-stranded ribonucleic acid during in vitro transcription. Background Art
[0002] mRNA vaccine is a new technology that combines molecular biology and immunology and is closely related to gene therapy. In the past decade, mRNA vaccines have been effective in immunizing against influenza virus, Zika virus and rabies virus. Especially after the outbreak of the new coronavirus pandemic, mRNA vaccines have gradually become a research hotspot due to their advantages such as fast development speed, high safety, scalability and high efficiency. Non-replicative mRNA is usually prepared by in vitro transcription. Using linearized plasmid DNA as a template, the target mRNA is synthesized by RNA polymerase through an enzymatic reaction, and then the 5' end of the mRNA is capped and the 3' end is tailed. Therefore, the sample obtained by in vitro transcription usually includes impurities such as RNA polymerase, residual NTP, DNA template, dsRNA and mRNA with abnormally terminated transcription. Among them, dsRNA impurities have a very large impact on the effectiveness and safety of mRNA vaccines, such as reducing translation efficiency, causing inflammatory response and immune stress response, etc. Therefore, it is particularly important to reduce dsRNA in mRNA products.
[0003] The formation of dsRNA during in vitro transcription is primarily based on two mechanisms. The first is based on RNA-dependent RNA polymerase. If the 3' end of the mRNA produced by in vitro transcription has a certain degree of complementarity, it may undergo reverse folding. Under the action of T7 polymerase, it is extended using the target RNA as a template, forming a cis-3'-end extended dsRNA. Alternatively, short transcripts specifically bind to the complementary sequence of the target mRNA under annealing conditions, forming short transcript-dsRNA. The second is based on DNA-dependent, promoter-independent RNA polymerase. Transcription uses the non-template strand as a template. Under the action of the promoter-independent T7 polymerase, antisense RNA is transcribed, which is complementary to the target RNA to form dsRNA. Current methods for removing dsRNA from transcripts include purifying the mRNA after in vitro transcription to remove dsRNA or reducing dsRNA production during in vitro transcription. Markus et al. used cellulose chromatography to enable dsRNA to specifically bind to cellulose in an ethanol system, reducing dsRNA levels by over 90%. US20200071689A1 discloses a method for removing dsRNA from in vitro transcription products. Adding dsRNA from the transcribed mRNA digestion product to the RNase III digestion system removes dsRNA while protecting the mRNA from enzymatic digestion. However, this method can damage the secondary structure of the mRNA during purification or enzymatic digestion, reducing its integrity. Therefore, the enzyme must be removed afterward, increasing process costs and reducing yield, resulting in significant limitations. Katalin et al. separated dsRNA from mRNA using HPLC, and found that mRNA translation levels in cells increased by 10- to 1000-fold. Although these purification methods can reduce dsRNA levels in mRNA, mRNA is unstable and easily degraded during purification.
[0004] Reducing the production of dsRNA during in vitro transcription is to reduce the level of dsRNA from the source. Current research mainly focuses on the following three aspects. (1) DNA template sequence transformation and modification. Adding a polyA tail sequence to the DNA template can reduce the production of antisense dsRNA; during RNA synthesis, N1-methyl-pseudouridine modified RNA may help reduce the synthesis of antisense RNA chains, increase protein expression and reduce immunogenicity. Adding a DNA sequence complementary to the 3' end can effectively prevent 3' end self-extension by competing to capture DNA, reducing the production of 3' end self-extension dsRNA. (2) Transformation and modification of RNA polymerase. MONICA et al. used heat-resistant RNAP to perform in vitro transcription reactions at high temperatures, and the 3' end extension of dsRNA was significantly reduced, and the mRNA product showed lower immunogenicity. Heng Xia et al. found that the RNA polymerase encoded by the psychrophilic phage VSW-3 significantly reduced the dsRNA level in RNA synthesized at low temperatures (4-25℃), among which the 3' end extension and full-length dsRNA were almost completely eliminated. Moderna modified the amino acid sequence of T7 polymerase. After the G47A+884G mutation of T7 polymerase, the production of dsRNA can be reduced. (3) Regulating the in vitro transcription process. Reducing the magnesium ion concentration to below 5mM during in vitro transcription can reduce the production of 3'-end extended and antisense dsRNA. Carrying out in vitro transcription reaction under high salt conditions can reduce the production of dsRNA by inhibiting the recombination of RNA products, and immobilizing the promoter DNA and T7 RNA polymerase to improve the total yield and purity of the coding RNA. CN115087456 discloses a method for reducing the formation of double-stranded RNA in the transcription system. Adding at least one chaotropic agent to the transcription initiation reaction mixture can reduce or inhibit the interaction between bases and reduce the formation of dsRNA during RNA preparation. These methods can all reduce the production of dsRNA to a certain extent. However, high temperature transcription and specific competitive sites will increase the economic burden on mRNA production, especially for industrial production. While chaotropic salts can reduce dsRNA synthesis, they are commonly used protein denaturants that can affect the structure and activity of the T7 enzyme. Furthermore, the addition of denaturants can introduce new impurities. Furthermore, reducing the magnesium ion concentration in the transcription system and adding denaturants can also affect mRNA yield. Therefore, it is crucial to find other methods that can reduce dsRNA production without affecting in vitro transcription and the T7 enzyme.
[0005] In summary, the current methods for removing and reducing dsRNA levels in transcription systems have the problems of complex operation, high cost, low mRNA yield and instability. How to provide a method with high efficiency in reducing dsRNA, high mRNA yield, low cost and good mRNA stability, and then commercialize it (i.e., solidify it into a kit) has become one of the problems to be solved in the current field of mRNA in vitro synthesis and separation and purification technology. The present invention proposes a method for adding a negatively charged solid phase medium during in vitro transcription to reduce dsRNA yield and improve mRNA yield and stability. The solid phase medium used in this method is insoluble in water and will not contaminate the transcription system; after transcription is completed, the solid phase medium is easy to separate and the operation is simple; the solid phase medium can be reused after appropriate treatment, is low in cost, and is easy to use for large-scale production. It was also surprisingly found that the mRNA transfection efficiency prepared by solid phase regulation was improved and the expression of immune factors was reduced.
[0006] Summary of the Invention
[0007] In response to the above-mentioned technical limitations, namely, the problems of complex operation, high cost, low mRNA yield and poor stability in current methods for removing dsRNA from mRNA, the present invention proposes a method for preparing mRNA with high yield that reduces or inhibits the formation of double-stranded ribonucleic acid (dsRNA) during in vitro transcription. This method achieves a simple and efficient reduction in dsRNA production, increases mRNA yield, and ensures mRNA stability. The method has the technical advantages of being simple to operate, pollution-free, low-cost, easy to scale up, and having a reusable solid phase medium. At the same time, the present invention also develops a kit for in vitro transcription and synthesis of mRNA based on the above method that can reduce or inhibit dsRNA formation, overcoming the shortcomings and defects mentioned in the background art.
[0008] To achieve the above objectives, this application adopts the following technical solutions:
[0009] The invention of the present application is to provide a method for preparing mRNA with high yield by reducing or inhibiting the formation of double-stranded ribonucleic acid during in vitro transcription, wherein the preparation method is to add a solid phase medium during the transcription process.
[0010] Optionally, in the above-mentioned high-yield mRNA preparation method, the solid phase medium is a medium modified with negatively charged groups.
[0011] The modification can be performed at any position of the solid phase medium, for example, the surface of the solid phase medium can be modified with a negatively charged group, or the interior of the solid phase medium can be modified with a negatively charged group.
[0012] Optionally, in the above-mentioned high-yield mRNA preparation method, the negatively charged groups modified on the solid phase medium are one or more of sulfonic acid group -SO3, methylsulfonic acid group -CH2SO3, ethylsulfonic acid group -(CH2)2SO3, propylsulfonic acid group -(CH2)3SO3, phosphate group PO3, carboxylic acid group -COO, formic acid group -CH2COO, hydroxyl group -OH, polyadenylic acid Ploy A, polythymidylic acid Ploy T, polyuridylic acid Ploy U, polyguanylic acid Ploy G and polycytidylic acid Ploy C.
[0013] Among them, the polymerization degree n of Ploy A (polyadenylic acid), Ploy T (polythymidylic acid), Ploy U (polyuridine monophosphate), Ploy G (polyguanylic acid), and Ploy C (polycytidylic acid) is 1 to 100; the polymerization degree and are selected from 1, 5, 10, 15, 20, 25, 50, 75, and 100.
[0014] Optionally, in the above-mentioned high-yield mRNA preparation method, the solid phase medium is in the form of one or more of granular, membrane-like and sheet-like.
[0015] Optionally, the above-mentioned high-yield mRNA preparation method,
[0016] The granular solid phase medium includes one or more of microspheres and nanoparticles;
[0017] The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials;
[0018] The organic material includes one or more of natural polysaccharides and synthetic polymers;
[0019] The natural polysaccharide organic material includes one or more of cellulose, glucan, agarose, chitosan and konjac glucomannan;
[0020] The synthetic polymer includes one or more of styrene polymers, acrylic polymers and polyvinyl acid polymers;
[0021] The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite;
[0022] The functional material includes one or more of a magnetic material and a thermosensitive material;
[0023] The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane;
[0024] The sheet-like solid phase medium includes carbon nanotubes.
[0025] Optionally, the above-mentioned high-yield mRNA preparation method comprises the following steps:
[0026] S1. Pretreatment of the solid phase medium: After washing the solid phase medium with sterile enzyme-free water, equilibrate it with a buffer solution, shake and equilibrate it, and then drain it; preferably, the buffer solution comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer, and HEPES buffer; the shaking equilibration time is 5-240 minutes; the equilibrated solid phase medium is drained through a sintered glass filter; the buffer solution is preferably Tris-HCl buffer or phosphate buffer; the buffer solution concentration is 0.01-1M, and can be selected from 0.01M, 0.05M, 0.1M, 0.3M, 0.5M, 0.7M, and 1M; the shaking equilibration time is preferably 60-240 minutes, and can be selected from 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, and 240 minutes;
[0027] S2. Prepare an mRNA in vitro transcription system, and add a solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA; the timing of adding the solid phase medium to the transcription system mixture is the transcription initiation stage, the transcription process stage or the post-transcription stage, preferably the transcription initiation stage; the amount of the solid phase medium added is 1-1000 mg / ml, preferably 10-600 mg / ml, more preferably 10-200 mg / ml, and can be selected from 10 mg / ml, 50 mg / ml, 100 mg / ml, and 200 mg / ml; the transcription system mixture includes a reaction buffer, a DNA template, NTP, a T7 polymerase, an RNase A inhibitor and pyrophosphatase; the transcription reaction temperature is 20-60°C, and can be selected from 20°C, 37°C, 55°C, and 60°C, preferably 37°C, and the transcription time is 4h (0h is the transcription start stage, and >4h is the post-transcription stage); the concentration of the above-mentioned NTP can be 2-8M, and ATP in NTP includes natural ATP, N1-methyladenosine (m1A), and N6-methyladenosine (m6A); CTP includes natural CTP or 5-methylcytidine (m5C); UTP includes natural UTP, 5-methoxyuridine (5moU), pseudouridine (ψ) or N1-methylpseudouridine (m1ψ); cap analogs can also be added to the transcription system of step S2 for co-transcriptional capping, and cap analogs include: CAP GAG, CAP GAG (3'OMe) or CAP GAG (m6A).
[0028] S3. After transcription is completed, the supernatant is collected by centrifugation or gravity sedimentation to obtain an mRNA solution; the centrifugation speed is 8000-12000 rpm / min, preferably 10000 rpm / min; the centrifugation time is 1-3 min, preferably 2 min.
[0029] The second invention point of the present application is to provide a kit for in vitro transcription and synthesis of mRNA that can reduce or inhibit the formation of dsRNA. The kit adopts the above-mentioned method for high-yield preparation of mRNA that reduces or inhibits the formation of double-stranded ribonucleic acid during in vitro transcription. The kit includes a solid phase medium, a medium balance solution / buffer, a transcription reaction solution, a positive control DNA, NTP, T7 polymerase, an RNase A inhibitor, sterile enzyme-free water and pyrophosphatase.
[0030] Optionally, in the above-mentioned kit, the solid phase medium is a medium modified with negatively charged groups; the negatively charged groups include one or more of sulfonic acid group -SO3, methylsulfonic acid group -CH2SO3, ethylsulfonic acid group -(CH2)2SO3, propylsulfonic acid group -(CH2)3SO3, phosphate group PO3, carboxylic acid group -COO, formic acid group -CH2COO, hydroxyl group -OH, polyadenylic acid Ploy A, polythymidylic acid Ploy T, polyuridine acid Ploy U, polyguanylic acid Ploy G and polycytidylic acid Ploy C; wherein the degree of polymerization n of Ploy A (polyadenylic acid), Ploy T (polythymidylic acid), Ploy U (polyuridine acid), Ploy G (polyguanylic acid) and Ploy C (polycytidylic acid) is 1 to 100; the degree of polymerization and are selected from 1, 5, 10, 15, 20, 25, 50, 75, 100;
[0031] The solid phase medium is in the form of one or more of granules, films and sheets;
[0032] The granular solid phase medium includes one or more of microspheres and nanoparticles;
[0033] The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials;
[0034] The organic material includes one or more of natural polysaccharides and synthetic polymers;
[0035] The natural polysaccharide organic material includes one or more of cellulose, glucan, agarose, chitosan and konjac glucomannan;
[0036] The synthetic polymer includes one or more of styrene polymers, acrylic polymers and polyvinyl acid polymers;
[0037] The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite;
[0038] The functional material includes one or more of a magnetic material and a thermosensitive material;
[0039] The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane;
[0040] The sheet-like solid phase medium includes carbon nanotubes;
[0041] The medium balancing solution / buffer comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer and HEPES buffer;
[0042] Preferably, the medium balancing solution / buffer is Tris-HCl buffer or phosphate buffer;
[0043] Preferably, the buffer concentration is 0.01-1M, and can be selected from 0.01M, 0.05M, 0.1M, 0.3M, 0.5M, 0.7M, and 1M;
[0044] The transcription reaction solution comprises a basic buffer, an inorganic salt and a reducing agent; the basic buffer comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer and HEPES buffer; the inorganic salt comprises one or more of NaCl, KCl, MgCl2, Na2SO4, K2SO4, MgSO4; the reducing agent comprises one or more of DTT, mercaptoethanol and reduced glutathione.
[0045] The third invention of the present invention is to provide a method for using the above-mentioned kit, comprising the following steps:
[0046] T1. Pre-treat the solid phase medium in the kit by washing it with sterile, enzyme-free water and then equilibrating it with a medium equilibration solution / buffer.
[0047] T2. Prepare an mRNA in vitro transcription system using the reagents in the kit, and add the pretreated solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA;
[0048] T3. After transcription is completed, collect the supernatant by centrifugation or gravity sedimentation to obtain the mRNA solution.
[0049] Optionally, in the method for using the above-mentioned kit, in step T1, the pretreatment is to wash the solid phase medium with sterile enzyme-free water, then balance it with a medium balance solution, shake it and then drain it; the shaking balance time is 5-240 min; preferably, the shaking balance time is preferably 60-240 min, and can be selected from 60 min, 90 min, 120 min, 150 min, 180 min, 210 min, and 240 min; in step T2, the pretreated solid phase medium is added to the transcription system mixture at the transcription initiation stage, the transcription process stage or the post-transcription stage, preferably the transcription initiation stage; the amount of solid phase medium added is 1-1000 mg / ml, preferably 10-200 mg / ml; the transcription system mixture includes transcription reaction solution, DNA template, NTP, T7 polymerase, RNase A inhibitor and pyrophosphatase; the transcription reaction temperature is 20-60°C.
[0050] The amount of solid phase medium added is 1-1000 mg / ml, preferably 10-600 mg / ml, more preferably 10-200 mg / ml, and can be selected from 10 mg / ml, 50 mg / ml, 100 mg / ml, and 200 mg / ml.
[0051] The transcription reaction temperature is 20-60°C, which can be selected from 20°C, 37°C, 55°C, 60°C, preferably 37°C, and the transcription time is 4h (0h is the transcription start stage, >4h is the post-transcription stage).
[0052] The concentration of NTP can be 2 to 8 M. ATP in NTP includes natural ATP, N1-methyladenosine (m1A), and N6-methyladenosine (m6A); CTP includes natural CTP or 5-methylcytidine (m5C); UTP includes natural UTP, 5-methoxyuridine (5moU), pseudouridine (ψ), or N1-methylpseudouridine (m1ψ).
[0053] Cap analogs may also be added to the transcription system in step T2 for co-transcriptional capping. Cap analogs include: CAP GAG, CAP GAG (3'OMe) or CAP GAG (m6A).
[0054] Compared with the prior art, this application has the following advantages:
[0055] The present invention provides a high-yield mRNA preparation method and kit that reduces or inhibits the formation of double-stranded RNA during in vitro transcription. By adding different types of negatively charged solid-phase media to the in vitro transcription process, the production of dsRNA is reduced through interface regulation, while mRNA yield and stability are increased. Furthermore, the mRNA transfection efficiency prepared by solid-phase regulation is improved, and immune factor expression is reduced. The solid-phase media used in this method and kit is insoluble in water and does not contaminate the transcription system. After transcription is complete, the solid-phase media is easily separated, making the operation simple. After appropriate treatment, the solid-phase media can be reused, resulting in low cost and easy scalability to industrial-scale production. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIG1 shows the HPLC detection spectra of Example 3-1 and Comparative Examples 1 and 2.
[0057] Figure 2 shows the relative mRNA yields calculated based on the peak areas detected by HPLC.
[0058] FIG3 shows the mRNA yields detected by agarose gel electrophoresis in Example 3-1 and Comparative Examples 1 and 2.
[0059] FIG4 shows the dot blot detection of dsRNA yields in Example 3-1 and Comparative Examples 1 and 2.
[0060] FIG5 shows the HPLC detection spectra of Example 3-1 and Comparative Example 4.
[0061] FIG6 shows the mRNA yields detected by agarose gel electrophoresis in Example 3-1 and Comparative Example 4.
[0062] FIG7 shows the dot blot detection of dsRNA yields in Example 3-1 and Comparative Example 4.
[0063] FIG8 shows the transfection efficiency of mRNA prepared by the method of Example 20 measured in Example 21.
[0064] FIG9 shows the IFN-β levels in cells transfected with mRNA prepared by the method of Example 20, as measured in Example 21. DETAILED DESCRIPTION
[0065] To make the purpose, technical solutions and advantages of this application more clear, this application is further described in detail below. However, it should be understood that the description herein is only used to explain this application and is not intended to limit the scope of this application.
[0066] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are intended solely for the purpose of describing specific embodiments and are not intended to limit this application. The reagents and instruments used herein are commercially available, and the characterization methods involved can be found in the relevant descriptions in the prior art and will not be further elaborated herein.
[0067] In order to further understand the present application, the present application is further described in detail below in conjunction with the best embodiment.
[0068] Example 1
[0069] The invention discloses a method for preparing mRNA with high yield, which reduces or inhibits the formation of double-stranded ribonucleic acid during in vitro transcription. The method comprises adding a solid phase medium during the transcription process.
[0070] The solid phase medium is modified with negatively charged groups.
[0071] The modification can be performed at any position of the solid phase medium, for example, the surface of the solid phase medium can be modified with a negatively charged group, or the interior of the solid phase medium can be modified with a negatively charged group.
[0072] The negatively charged groups modified on the solid phase medium are one or more of sulfonic acid group -SO3, methylsulfonic acid group -CH2SO3, ethylsulfonic acid group -(CH2)2SO3, propylsulfonic acid group -(CH2)3SO3, phosphate group PO3, carboxylic acid group -COO, formic acid group -CH2COO, hydroxyl group -OH, polyadenylic acid Ploy A, polythymidylic acid Ploy T, polyuridylic acid Ploy U, polyguanylic acid Ploy G and polycytidylic acid Ploy C.
[0073] Among them, the polymerization degree n of Ploy A (polyadenylic acid), Ploy T (polythymidylic acid), Ploy U (polyuridine monophosphate), Ploy G (polyguanylic acid), and Ploy C (polycytidylic acid) is 1 to 100; the polymerization degree and are selected from 1, 5, 10, 15, 20, 25, 50, 75, and 100.
[0074] The solid phase medium is in the form of one or more of granules, films and sheets.
[0075] The granular solid phase medium includes one or more of microspheres and nanoparticles;
[0076] The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials;
[0077] The organic material includes one or more of natural polysaccharides and synthetic polymers;
[0078] The natural polysaccharide organic material includes one or more of cellulose, glucan, agarose, chitosan and konjac glucomannan;
[0079] The synthetic polymer includes one or more of a styrene polymer, an acrylic polymer, and a polyvinyl acid polymer;
[0080] The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite;
[0081] The functional material includes one or more of a magnetic material and a thermosensitive material;
[0082] The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane;
[0083] The sheet-like solid phase medium includes carbon nanotubes.
[0084] The preparation method comprises the following steps:
[0085] S1. Pretreatment of the solid phase medium: After washing the solid phase medium with sterile enzyme-free water, equilibrate it with a buffer solution, shake and equilibrate it, and then drain it; preferably, the buffer solution comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer, and HEPES buffer; the shaking equilibration time is 5-240 minutes; the equilibrated solid phase medium is drained through a sintered glass filter; the buffer solution is preferably Tris-HCl buffer or phosphate buffer; the buffer solution concentration is 0.01-1M, and can be selected from 0.01M, 0.05M, 0.1M, 0.3M, 0.5M, 0.7M, and 1M; the shaking equilibration time is preferably 60-240 minutes, and can be selected from 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, and 240 minutes;
[0086] Prepare an mRNA in vitro transcription system, and add a solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA; the timing of adding the solid phase medium to the transcription system mixture is the transcription initiation stage, the transcription process stage or the post-transcription stage, preferably the transcription initiation stage; the amount of the solid phase medium added is 1-1000 mg / ml, preferably 10-600 mg / ml, more preferably 10-200 mg / ml, and can be selected from 10 mg / ml, 50 mg / ml, 100 mg / ml, and 200 mg / ml; the transcription system mixture includes a reaction buffer, a DNA template, NTP, a T7 polymerase, an RNase A inhibitor and pyrophosphatase; the transcription reaction temperature is 20-60°C, and can be selected from 20°C, 37°C, 55°C, and 60°C, preferably 37°C, and the transcription time is 4h (0h is the transcription start stage, and >4h is the post-transcription stage); the concentration of the above-mentioned NTP can be 2-8M, and ATP in NTP includes natural ATP, N1-methyladenosine (m1A), and N6-methyladenosine (m6A); CTP includes natural CTP or 5-methylcytidine (m5C); UTP includes natural UTP, 5-methoxyuridine (5moU), pseudouridine (ψ) or N1-methylpseudouridine (m1ψ); cap analogs can also be added to the transcription system for co-transcriptional capping, and cap analogs include: CAP GAG, CAP GAG (3'OMe) or CAP GAG (m6A).
[0087] S2. After transcription is completed, the supernatant is collected by centrifugation or gravity sedimentation to obtain an mRNA solution; the centrifugation speed is 8000-12000 rpm / min, preferably 10000 rpm / min; the centrifugation time is 1-3 min, preferably 2 min.
[0088] The present application also provides a kit for in vitro transcription and synthesis of mRNA that can reduce or inhibit the formation of dsRNA. The kit adopts the above-mentioned method for high-yield preparation of mRNA that reduces or inhibits the formation of double-stranded ribonucleic acid during in vitro transcription. The kit includes a solid phase medium, a medium balance solution / buffer, a transcription reaction solution, a positive control DNA, NTP, T7 polymerase, an RNase A inhibitor, sterile enzyme-free water and pyrophosphatase.
[0089] In the kit, the solid phase medium is a medium modified with negatively charged groups; the negatively charged groups include one or more of sulfonic acid group -SO3, methylsulfonic acid group -CH2SO3, ethylsulfonic acid group -(CH2)2SO3, propylsulfonic acid group -(CH2)3SO3, phosphate group PO3, carboxylic acid group -COO, formic acid group -CH2COO, hydroxyl group -OH, polyadenylic acid Ploy A, polythymidylic acid Ploy T, polyuridine acid Ploy U, polyguanylic acid Ploy G and polycytidylic acid Ploy C; wherein the polymerization degree n of Ploy A (polyadenylic acid), Ploy T (polythymidylic acid), Ploy U (polyuridine acid), Ploy G (polyguanylic acid) and Ploy C (polycytidylic acid) is 1 to 100; the polymerization degree and are selected from 1, 5, 10, 15, 20, 25, 50, 75 and 100;
[0090] The solid phase medium is in the form of one or more of granular, film-like and sheet-like;
[0091] The granular solid phase medium includes one or more of microspheres and nanoparticles;
[0092] The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials;
[0093] The organic material includes one or more of natural polysaccharides and synthetic polymers;
[0094] The natural polysaccharide organic material includes one or more of cellulose, glucan, agarose, chitosan and konjac glucomannan;
[0095] The synthetic polymer includes one or more of a styrene polymer, an acrylic polymer, and a polyvinyl acid polymer;
[0096] The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite;
[0097] The functional material includes one or more of a magnetic material and a thermosensitive material;
[0098] The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane;
[0099] The sheet-like solid phase medium includes carbon nanotubes;
[0100] The medium balancing solution / buffer comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer and HEPES buffer;
[0101] Preferably, the medium balancing solution / buffer is Tris-HCl buffer or phosphate buffer;
[0102] Preferably, the buffer concentration is 0.01-1M, and can be selected from 0.01M, 0.05M, 0.1M, 0.3M, 0.5M, 0.7M, and 1M;
[0103] The transcription reaction solution includes a basic buffer, an inorganic salt, and a reducing agent; the basic buffer includes one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer, and HEPES buffer; the inorganic salt includes one or more of NaCl, KCl, MgCl2, Na2SO4, K2SO4, and MgSO4; and the reducing agent includes one or more of DTT, mercaptoethanol, and reduced glutathione.
[0104] This application also provides a method for using the above kit, comprising the following steps:
[0105] T1. Pre-treat the solid phase medium in the kit by washing it with sterile enzyme-free water and then equilibrating it with a medium equilibration solution / buffer.
[0106] T2. Prepare an mRNA in vitro transcription system using the preparation in the kit, and add the pretreated solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA;
[0107] T3. After transcription is completed, collect the supernatant by centrifugation or gravity sedimentation to obtain the mRNA solution.
[0108] In step T1, the pretreatment is to wash the solid phase medium with sterile enzyme-free water, then balance it with a medium balance solution, shake it and then drain it; the shaking balance time is 5-240 minutes; preferably, the shaking balance time is preferably 60-240 minutes, and can be selected from 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, and 240 minutes; in step T2, the pretreated solid phase medium is added to the transcription system mixture at the transcription initiation stage, the transcription process stage, or the post-transcription stage, preferably the transcription initiation stage; the amount of the solid phase medium added is 1-1000 mg / ml, preferably 10-200 mg / ml; the transcription system mixture includes a transcription reaction solution, a DNA template, NTP, T7 polymerase, an RNase A inhibitor, and a pyrophosphatase; and the transcription reaction temperature is 20-60°C.
[0109] The amount of solid phase medium added is 1-1000 mg / ml, preferably 10-600 mg / ml, more preferably 10-200 mg / ml, and can be selected from 10 mg / ml, 50 mg / ml, 100 mg / ml, and 200 mg / ml.
[0110] The transcription reaction temperature is 20-60°C, which can be selected from 20°C, 37°C, 55°C, 60°C, preferably 37°C, and the transcription time is 4h (0h is the transcription start stage, >4h is the post-transcription stage).
[0111] The concentration of NTP can be 2 to 8 M. ATP in NTP includes natural ATP, N1-methyladenosine (m1A), and N6-methyladenosine (m6A); CTP includes natural CTP or 5-methylcytidine (m5C); UTP includes natural UTP, 5-methoxyuridine (5moU), pseudouridine (ψ), or N1-methylpseudouridine (m1ψ).
[0112] Cap analogs may also be added to the transcription system in step T2 for co-transcriptional capping. Cap analogs include: CAP GAG, CAP GAG (3'OMe) or CAP GAG (m6A).
[0113] Example 2
[0114] A method for preparing mRNA in high yield, comprising the following steps:
[0115] S1. Pretreatment of solid phase media:
[0116] The agarose microspheres modified with sulfonic acid group -SO3 were washed with sterile enzyme-free water, and then washed and balanced with 0.05M Tris-HCl buffer prepared with sterile enzyme-free water for 240 minutes. The microspheres were settled and separated by centrifugation or gravity before use.
[0117] S2. mRNA in vitro transcription:
[0118] Prepare an mRNA in vitro transcription system. At the start of the transcription reaction, i.e., at the 0h stage of the reaction, add the solid phase medium to the transcription system mixture to perform the transcription reaction to prepare mRNA. The amount of solid phase medium added is 100 mg / ml. The mRNA transcription system (reaction system 100 μL) is prepared as follows:
[0119] (1) Prepare 10× Transcription Buffer: 400 mM Tris-HCl (pH 7.9), 60 mM MgCl2, 100 mM DTT (dithiothreitol), and 20 mM spermidine;
[0120] (2) Place the required T7 RNA Polymerase, RNase inhibitor, and pyrophosphatase on ice; Mix ATP, CTP, GTP, and UTP (pseudouridine-modified UTP, N1-methylpseudouridine-modified UTP, 5-methylcytidine-modified CTP, and N1-methyladenosine-modified ATP) and place them on ice. Sterile enzyme-free water, DNA template, and 10× Transcription Buffer should be placed at room temperature for later use (if a co-transcription capping system is used, the cap analogue should be CAP GAG, CAP GAG (3'OMe), or CAP GAG (m6A)).
[0121] (3) Add 10 μL of 10× Transcription Buffer, 41.5 μL of RNase-Free Water, 8 μL of NTP (nucleoside triphosphate), 30 μL of DNA template, 5 μL of T7 RNA Polymerase, 4 μL of RNase inhibitor, and 1.5 μL of pyrophosphatase (if it is a co-transcription capping system, add 2 μL of cap analog) to a sterile enzyme-free centrifuge tube, gently mix all components, and incubate at 37°C for 4 h;
[0122] S3. After transcription is completed, collect the supernatant by centrifugation or gravity sedimentation to obtain the mRNA solution.
[0123] In the kit, specifically:
[0124] The agarose-dextran microspheres modified with sulfonic acid group -SO3 were washed with sterile enzyme-free water, and then equilibrated with 0.05M Tris-HCl medium equilibration buffer prepared with sterile enzyme-free water for 240 minutes. The microspheres were settled and separated by centrifugation or gravity before use.
[0125] At the start of the transcription reaction, i.e., at the 0h stage of the reaction, the pre-equilibrated solid phase medium was added to the transcription system mixture. The reaction system was 100 μL, and the transcription reaction was performed to prepare mRNA. The specific amount of each component in the kit was as follows:
[0126] 1) The amount of solid phase medium added is 100 mg / ml;
[0127] 2) 10 μl of 10× Transcription Buffer: 400 mM Tris-HCl (pH 7.9), 60 mM MgCl2, 100 mM DTT (dithiothreitol), 20 mM spermidine;
[0128] 3) 30 μL of green fluorescent protein DNA template;
[0129] 4) 2 μL each of ATP, CTP, GTP, and UTP (if using a co-transcriptional capping system, add 2 μL of cap analog);
[0130] 5) RNase inhibitor (4 μL) and pyrophosphatase (1.5 μL);
[0131] 6) Add 5 μL of T7 RNA Polymerase;
[0132] 7) Add sterile enzyme-free water to make up to 100 μL.
[0133] Gently mix the above components and incubate at 37°C for 4 hours. After transcription is complete, collect the supernatant by centrifugation or gravity sedimentation to obtain the mRNA solution.
[0134] Example 3
[0135] Different types of solid phase media modified with sulfonic acid groups for in vitro transcription:
[0136] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0137] The method was basically the same as that described in Example 2, except that different sulfonic acid-modified solid phase media were added. 5 mg of five different sulfonic acid-modified solid phase media were added to the transcription system, and five 100 μL transcription mixtures were prepared using the green fluorescent protein gene as a template.
[0138] The kits were used using the same kits and methods as described above, differing in the matrix of the solid phase media used: sulfonic acid-modified agarose microspheres, nitrocellulose membranes, silica matrices, nanofibers, and magnetic microspheres. 5 mg of each of the five different sulfonic acid-modified solid phase media was added to the transcription system, and transcription was performed using the green fluorescent protein gene as a template.
[0139] Table 1 shows the five different solid phase media modified with sulfonic acid groups selected for use.
[0140] Table 1
[0141] Gently mix all components and incubate at 37°C for 4 hours. After transcription is complete, separate the transcription mixture and the solid phase medium.
[0142] Example 4
[0143] Agarose microsphere media modified with different groups were added during in vitro transcription:
[0144] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0145] The method is basically the same as that described in Example 2, except that the added dextran microsphere solid phase medium is modified with five different groups. 10 mg of dextran microsphere solid phase medium modified with five different negatively charged groups is added to the transcription system, and five 100 μL transcription mixtures with the green fluorescent protein gene as a template are prepared.
[0146] The use of the kit is roughly the same as that described in Example 2, except that the solid phase medium in the kit is agarose microspheres modified with five different groups, and 10 mg of five different negatively charged group-modified dextran microsphere solid phase media are added to the transcription system, and transcription is performed using the green fluorescent protein gene as a template.
[0147] Table 2 shows the five different negatively charged groups selected for surface modification of the dextran microsphere solid phase medium.
[0148] Table 2
[0149] Gently mix all components and incubate at 37°C for 4 hours. After transcription is complete, centrifuge at 12,000 rpm for 2 minutes to separate the transcription mixture and microspheres. When using a polythymidine-modified solid phase medium, a small amount of transcribed mRNA will be adsorbed. Add 100 μL of 20 mM Tris-HCl + 1 M NaCl (pH 7.0) to the microspheres for elution and centrifuge at 12,000 rpm for 2 minutes to separate the transcription mixture and microspheres. Then, add 100 μL of sterile, enzyme-free water to the microspheres, place on a shaker, and elute at 180 rpm at 60°C for 1 hour. Centrifuge at 12,000 rpm for 2 minutes to separate the eluted sample and microspheres, and the small amount of mRNA adsorbed on the medium can be recovered.
[0150] Example 5
[0151] Solid phase media with different concentrations for in vitro transcription:
[0152] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0153] The method is substantially the same as that described in Example 2, except that the concentration (addition amount) of the added sulfonic acid group-modified dextran-agarose solid phase medium is different. The sulfonic acid group-modified dextran-agarose solid phase medium is added to the transcription system at 6 concentrations and amounts, and 6 100 μL transcription mixtures with the green fluorescent protein gene as a template are prepared.
[0154] The use of the kit is substantially the same as that described in Example 2, except that the concentration (addition amount) of the added sulfonic acid group-modified dextran-agarose solid phase medium is different. The sulfonic acid group-modified dextran-agarose solid phase medium is added to the transcription system at 6 different concentrations, and transcription is performed using the green fluorescent protein gene as a template.
[0155] Table 3 shows the six sulfonic acid group-modified dextran-agarose solid phase media selected for use with different addition amounts.
[0156] Table 3
[0157] Gently mix all components and incubate at 37°C for 4 h. After transcription is complete, centrifuge at 12,000 rpm for 2 min to separate the transcription mixture and microspheres.
[0158] Example 6
[0159] Add solid phase medium at different times during in vitro transcription:
[0160] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0161] The method was substantially the same as that described in Example 2, except that 5 mg of sulfonic acid-modified agarose microsphere solid phase medium was added at different times. The equilibrated solid phase medium was added to the transcription system at four different times to prepare four 100 μL transcription mixtures using the green fluorescent protein gene as a template.
[0162] The use of the kit was similar to that described in Example 2, except that 5 mg of sulfonic acid-modified agarose microsphere solid phase medium was added at different times after the start of transcription. The equilibrated solid phase medium was added to the transcription system at four different times, and the transcription reaction was carried out using the green fluorescent protein gene as a template.
[0163] Table 4 shows the four different addition timings of the solid phase medium used in the in vitro transcription process.
[0164] Table 4
[0165] Gently mix all components and incubate at 37°C for 4 hours. After transcription is complete, separate the transcription mixture and microspheres.
[0166] Example 7
[0167] Solid phase media modified with groups of different polymer lengths for in vitro transcription:
[0168] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0169] The method is basically the same as that described in Example 2, except that 10 mg of solid phase medium added to the transcription system is a solid phase medium (polystyrene matrix) modified with four different degrees of polymerization of polythymine, and four 100 μL transcription mixtures are prepared with the green fluorescent protein gene as a template.
[0170] The use of the kit is roughly the same as that described in Example 2, except that the 10 mg solid phase medium added to the transcription system is a solid phase medium (polystyrene matrix) modified with polythymine of four different polymerization degrees, and in vitro transcription is performed using the gene of the foot-and-mouth disease protein as a template.
[0171] Table 5 shows the four different polymerization degrees of the polythymine-modified solid phase media (polystyrene matrix) selected for use.
[0172] Table 5
[0173] Gently mix all components and incubate at 37°C for 4 hours. After transcription is complete, centrifuge at 12,000 rpm for 2 minutes to separate the transcription mixture from the microspheres. This type of medium may adsorb a small amount of transcribed mRNA. To wash the microspheres, add 100 μL of 20 mM Tris-HCl + 1 M NaCl (pH 7.0) and centrifuge at 12,000 rpm for 2 minutes to separate the transcription mixture from the microspheres. Then, add 100 μL of sterile, enzyme-free water to the microspheres, place on a shaker, and elute at 180 rpm at 60°C for 1 hour. Centrifuge at 12,000 rpm for 2 minutes to separate the eluted sample and microspheres, allowing the small amount of mRNA adsorbed to the medium to be recovered.
[0174] Example 8
[0175] Different transcription temperatures in in vitro transcription systems:
[0176] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0177] The method was substantially the same as that described in Example 2, except that 5 mg of carboxylic acid-modified agarose matrix microsphere solid phase medium was added to the transcription system, and in vitro transcription was performed at three different temperatures to prepare three 100 μL transcription mixtures using the green fluorescent protein gene as a template.
[0178] The use of the kit is substantially the same as that described in Example 2, except that 5 mg of carboxylic acid-modified agarose matrix microsphere solid phase medium is added to the transcription system, and in vitro transcription is performed at three different temperatures.
[0179] Table 6 shows the three different in vitro transcription temperatures selected for use.
[0180] Table 6
[0181] After incubation for 4 h and transcription was complete, the transcription mixture and microspheres were separated by centrifugation at 12,000 rpm for 2 min.
[0182] Example 9
[0183] Adding solid phase media to in vitro transcription with different modified NTPs:
[0184] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0185] The method was substantially the same as that described in Example 2, except that the NTP added to the transcription system was modified in four different ways, and four 100 μL transcription mixtures were prepared using the green fluorescent protein gene as a template.
[0186] The use of the kit is substantially the same as that described in Example 2, except that the NTP added to the transcription system has undergone four different modifications.
[0187] Table 7 shows the four different NTP modifications selected for use in in vitro transcription.
[0188] Table 7
[0189] 5 mg of carboxylic acid-modified dextran microspheres were added to the transcription system, the components were gently mixed, and incubated at 37°C for 4 h. After transcription was completed, the transcription mixture and microspheres were separated by centrifugation at 12,000 rpm for 2 min.
[0190] Example 10
[0191] Reusing solid phase media in transcription systems:
[0192] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0193] The method is generally the same as that described in Example 2, except that 100 μL of a transcription mixture using the green fluorescent protein gene as a template is prepared, 5 mg of sulfonic acid-containing agarose-dextran microsphere medium is added, the components are gently mixed, and the mixture is incubated at 37°C for 4 h. After transcription is complete, the transcription mixture and microspheres are separated by centrifugation at 12,000 rpm for 2 min. 100 μL of 20 mM Tris-HCl (pH 7.0) is added to the microspheres for elution, and the mixture is separated by centrifugation at 12,000 rpm for 2 min. 100 μL of 20 mM Tris-HCl + 1 M NaCl (pH 7.0) is then added to the microspheres, and the mixture is eluted at 180 rpm at 60°C for 1 h on a shaker. The eluted sample and microspheres are separated by centrifugation at 12,000 rpm for 2 min.
[0194] The eluted microspheres were placed in 20 mM Tris-HCl (pH 7.0) buffer for re-equilibration, and the microspheres were reused twice according to the above steps.
[0195] In the use of the kit, the difference described in Example 2 is that 100 μL of a transcription mixture using the green fluorescent protein gene as a template is prepared, 5 mg of a sulfonic acid-containing agarose microsphere medium is added, the components are gently mixed, and the mixture is incubated at 37° C. for 4 hours. After transcription is completed, the transcription mixture and the microspheres are separated by centrifugation at 12,000 rpm for 2 minutes.
[0196] The microspheres were washed with 100 μL of 20 mM Tris-HCl (pH 7.0) and centrifuged at 12,000 rpm for 2 minutes to separate the transcription mixture from the microspheres. Then, 100 μL of 20 mM Tris-HCl + 1 M NaCl (pH 7.0) was added to the microspheres and eluted at 180 rpm at 60°C for 1 hour on a shaker. The eluted sample was then centrifuged at 12,000 rpm for 2 minutes to separate the microspheres.
[0197] The eluted microspheres were placed in 20 mM Tris-HCl (pH 7.0) buffer for re-equilibration, and the microspheres were reused twice according to the above steps.
[0198] Table 8 shows the number of times the solid phase medium was used during in vitro transcription.
[0199] Table 8
[0200] Example 11
[0201] Mixed use of multiple solid phase media:
[0202] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0203] The method was substantially the same as that described in Example 2, except that three groups of differently modified solid phase medium mixtures were added to the transcription system, and three 100 μL transcription mixtures were prepared using the green fluorescent protein gene as a template.
[0204] The use of the kit is substantially the same as that described in Example 2, except that three groups of differently modified solid phase medium mixtures are added to the transcription system.
[0205] Table 9 shows three different solid phase medium mixtures selected for use in in vitro transcription.
[0206] Table 9
[0207] Gently mix all components and incubate at 37°C for 4 h. After transcription is complete, centrifuge at 12,000 rpm for 2 min to separate the transcription mixture and the solid phase medium.
[0208] Comparative Example 1
[0209] Comparative Example 1 is a transcription system without adding a solid phase medium.
[0210] The operation process of the transcription system without solid phase medium is as follows: take 100 μL of the transcription mixture with the green fluorescent protein gene as the template, gently mix the components, and incubate at 37°C for 4 hours.
[0211] Comparative Example 2
[0212] Comparative Example 2 is a transcription system in which agarose microspheres without ligand modification are added. The difference from Group 1 of Example 3 (agarose microspheres modified with sulfonic acid groups) is that the surface of the agarose microspheres without ligand modification is not modified with negatively charged groups.
[0213] The transcription system using ligand-free agarose microspheres is as follows: 100 μL of a transcription mixture containing the green fluorescent protein gene as a template is added to 5 mg of ligand-free agarose microspheres. The mixture is gently mixed and incubated at 37°C for 4 hours. After transcription is complete, the mixture is separated from the microspheres by centrifugation at 12,000 rpm for 2 minutes. The microspheres are then eluted with 100 μL of 20 mM Tris-HCl (pH 7.0) and centrifuged at 12,000 rpm for 2 minutes to separate the mixture from the microspheres. The microspheres are then eluted with 100 μL of 20 mM Tris-HCl + 1 M NaCl (pH 7.0) and shaken at 180 rpm at 60°C for 1 hour. The eluted sample is then centrifuged at 12,000 rpm for 2 minutes to separate the microspheres.
[0214] Comparative Example 3
[0215] Comparative Example 3 is a transcription system in which agarose microspheres modified with positively charged groups are added. The difference from Group 1 of Example 3 (agarose microspheres modified with sulfonic acid groups) is that the modified groups on the agarose microspheres added in this comparative example are positively charged.
[0216] Example 12 (Test Example 1)
[0217] Agarose gel electrophoresis and HPLC were used to quantify the mRNA in the transcription samples, and Dot blot was used to quantify the dsRNA in the in vitro transcription system. The mRNA yield and dsRNA content obtained in Examples 3-11 were calculated. The results are listed in Table 10.
[0218] Relative mRNA yield (%) = mRNA concentration of the group with solid phase medium added / mRNA concentration of the group without solid phase medium added*100%.
[0219] dsRNA relative yield (%) = dsRNA content in mRNA of the group with solid phase medium added / dsRNA content in mRNA of the group without solid phase medium added*100%.
[0220] Table 10 compares the statistical results of the relative mRNA yield (%) and dsRNA yield (%) obtained in Comparative Examples 1-3 and Examples 3-11; wherein, the first item in Table 1 of Example 3 is represented by "Example 3-1", the second item in Table 1 of Example 3 is represented by "Example 3-2", and the rest are represented by the same analogy.
[0221] Table 10
[0222] Example 13 (Test Example 2)
[0223] HPLC test was performed on the first group of Example 3 (Example 3-1) and Comparative Examples 1 and 2. The samples after transcription were diluted 10 times and then quantitatively analyzed by HPLC.
[0224] mRNA quantification assay: Post-transcription samples were analyzed by HPLC using an Arc HPLC system (Waters, USA) on a SEC-2000 (300 × 7.8 mm) analytical column (Sepax, USA) with UV detection at 260 nm. For each run, 100 μl of sample was injected into a buffer containing 50 mM PB + 100 mM Na₂SO₄ (pH 7.0) and eluted at a flow rate of 0.6 ml / min for 30 min. mRNA in the transcription system was quantified by area integration based on the HPLC standard curve for mRNA quantification.
[0225] The HPLC detection spectra of Example 3-1 and Comparative Examples 1 and 2 are shown in FIG1 , and the relative mRNA yields calculated based on the peak areas are shown in FIG2 .
[0226] The results showed that the addition of sulfonic acid ligand-modified agarose microspheres to the transcription system increased the mRNA yield, while the addition of ligand-free agarose microspheres had no significant effect on the mRNA yield.
[0227] Example 14 (Test Example 3)
[0228] Agarose gel electrophoresis was performed on Example 3-1 and Comparative Examples 1 and 2. The test method was as follows: a 1.5% agarose gel was prepared, 3 μl of the transcribed sample was added to 7 μl of sterile enzyme-free water and 2 μl of 6x RNA loading buffer, and the mixture was heated at 65°C for 5 minutes. Then, 10 μl of the sample was immediately loaded on ice and subjected to agarose gel electrophoresis. The results are shown in Figure 3.
[0229] The results showed that the addition of sulfonic acid ligand-modified agarose microspheres to the transcription system increased the mRNA yield, while the addition of ligand-free agarose microspheres had no significant effect on the mRNA yield.
[0230] Example 15 (Test Example 4)
[0231] The dsRNA yield of Example 3-1 and Comparative Examples 1 and 2 was analyzed by the following test method: Dotblot method: the transcribed mRNA was diluted to 50 ng / μl. 2 μl of each sample was dropped onto a Nylon membrane. After air drying, it was blocked with a blocking solution (5% skim milk powder) for 1 hour. The blocking solution was removed and washed 3 times with TBST buffer (10 min / time); after adding a primary antibody and incubating at room temperature for 1 hour, the primary antibody was removed and washed 3 times with TBST buffer (10 min / time); after adding a secondary antibody and incubating at room temperature for 1 hour, the secondary antibody was removed and washed 3 times with TBST buffer (10 min / time). TCL luminescent liquid A and B were mixed in a ratio of 1:1, and 100 μl was evenly dropped on the membrane and photographed using a gel imager. The results are shown in Figure 4.
[0232] The results showed that the addition of sulfonic acid ligand-modified agarose microspheres solid phase medium during in vitro transcription could significantly reduce the production of dsRNA, while the addition of ligand-free agarose microspheres had no significant effect on the production of dsRNA.
[0233] Example 16
[0234] This Example 16 compares the mRNA stability in the transcription systems of Comparative Examples 1, 2, and 3-1. The difference from Comparative Examples 1, 2, and 3-1 is that after transcription is completed, the remaining intact mRNA content is measured after standing at room temperature for 12 hours and compared with the content after transcription is completed.
[0235] Table 11 is a comparison of the mRNA content remaining after each sample (Comparative Example 1, Comparative Example 2, and Example 3-1) was placed at room temperature for 12 hours and the content after each transcription was completed (relative remaining content %). The three samples are represented by "Comparative Example 1-12h", "Comparative Example 2-12h", and "Example 3-1-12h", respectively.
[0236] Table 11
[0237] The results showed that after 12 hours, mRNA in the in vitro transcription system and the transcription system with non-ligand-modified agarose microspheres showed significant degradation, while mRNA in the transcription system with sulfonate-modified agarose microspheres showed almost no degradation. Therefore, the addition of sulfonate-modified agarose microspheres to the in vitro transcription system can significantly improve mRNA stability.
[0238] Example 17
[0239] The medium equilibration buffer in the kit is different.
[0240] The method is substantially the same as that described in Example 2, except that the equilibration buffer of the solid phase medium is different.
[0241] Table 12 shows the equilibration buffer for the solid phase medium.
[0242] Table 12
[0243] Example 18
[0244] The transcription reaction solution in the kit is different.
[0245] The method is substantially the same as that described in Example 2, except that the transcription reaction solution is different.
[0246] Table 13 shows the compositions of different transcription reaction solutions.
[0247] Table 13
[0248] Comparative Example 4
[0249] Comparative Example 4 is a commercial transcription kit, that is, the kit does not contain a solid phase medium.
[0250] The procedure is as follows: Prepare 100 μL of a transcription mixture using the green fluorescent protein gene as a template: 1) 10 μL of 10× Transcription Buffer (400 mM Tris-HCl, pH 7.9), 60 mM MgCl2, 100 mM DTT (dithiothreitol), and 20 mM spermidine; 2) 30 μL of the green fluorescent protein DNA template; 3) 2 μL each of ATP, CTP, GTP, and UTP; 4) 4 μL of RNase inhibitor and 1.5 μL of pyrophosphatase; 5) 5 μL of T7 RNA Polymerase; 6) top up to 100 μL with sterile, enzyme-free water. Gently mix all components and incubate at 37°C for 4 hours.
[0251] Test Example 5
[0252] Agarose gel electrophoresis and HPLC were used to quantify the mRNA in the transcription samples, and Dot blot was used to quantify the dsRNA in the in vitro transcription system. The mRNA yield and dsRNA content were calculated. The results are listed in Table 14.
[0253] Relative mRNA yield (%) = mRNA concentration of the group with solid phase medium added / mRNA concentration of the group without solid phase medium added*100%.
[0254] dsRNA relative yield (%) = dsRNA content in mRNA of the group with solid phase medium added / dsRNA content in mRNA of the group without solid phase medium added*100%.
[0255] Table 14 compares the statistical results of the relative mRNA yield (%) and dsRNA yield (%) obtained in Comparative Example 4 and Examples 3-13; wherein, the first item in Table 1 of Example 3 is represented by "Example 3-1", the second item in Table 1 of Example 3 is represented by "Example 3-2", and the rest are represented by the same analogy.
[0256] Table 14
[0257] Example 19
[0258] This example is a comparative example of the stability of mRNA in the transcription products of Example 3-1 and Comparative Example 4.
[0259] After the transcription reactions of Example 3-1 and Comparative Example 4 were completed, the transcription products were placed at room temperature for 12 hours, and the intact mRNA in the transcription samples was quantitatively determined by agarose gel electrophoresis and HPLC.
[0260] Table 15 compares the mRNA content remaining after each sample (Example 3-1 and Comparative Example 4) was placed at room temperature for 12 hours with the content after each transcription was completed (relative remaining content %), and the two samples are represented by "Example 3-1-12h" and "Comparative Example 4-12h", respectively.
[0261] Table 15
[0262] The results showed that after 12 hours, the mRNA in the commercial kit's transcription system significantly degraded, while the mRNA in the transcription system containing sulfonic acid-modified agarose microspheres showed almost no degradation. Therefore, the addition of sulfonic acid-modified agarose microspheres to the kit of the present invention can significantly improve the stability of mRNA.
[0263] Test Example 6
[0264] mRNA quantification assay: Post-transcription samples were analyzed by HPLC using an Arc HPLC system (Waters, USA) on a SEC-2000 (300 × 7.8 mm) analytical column (Sepax, USA) with UV detection at 260 nm. For each run, 100 μl of sample was injected into a buffer containing 50 mM PB + 100 mM Na₂SO₄ (pH 7.0) and eluted at a flow rate of 0.6 ml / min for 30 min. mRNA in the transcription system was quantified by area integration based on the HPLC standard curve for mRNA quantification.
[0265] The HPLC detection spectra of Example 3-1 and Comparative Example 4 are shown in FIG5 .
[0266] The results showed that the kit of the present invention added agarose microsphere solid phase medium modified with sulfonic acid group to increase the yield of mRNA.
[0267] Test Example 7
[0268] Agarose gel electrophoresis was performed on the samples from the examples and comparative examples. The following testing method was used: a 1.5% agarose gel was prepared. 3 μl of the transcribed sample was added to 7 μl of sterile, enzyme-free water and 2 μl of 6x RNA loading buffer. The mixture was heated at 65°C for 5 minutes, and then 10 μl of the sample was immediately loaded onto the gel in an ice bath for electrophoresis. The results are shown in Figure 6.
[0269] The results showed that the kit of the present invention added agarose microsphere solid phase medium modified with sulfonic acid group to increase the yield of mRNA.
[0270] Test Example 8
[0271] The dsRNA yield of the examples and comparative samples was analyzed using the following test method: Dotblot method: the transcribed mRNA was diluted to 50 ng / μl. 2 μl of each sample was dropped onto a Nylon membrane, air-dried, and then blocked with a blocking solution (5% skim milk powder) for 1 hour. The blocking solution was removed and the membrane was washed three times with TBST buffer (10 min / time); after adding a primary antibody and incubating at room temperature for 1 hour, the primary antibody was removed and the membrane was washed three times with TBST buffer (10 min / time); after adding a secondary antibody and incubating at room temperature for 1 hour, the secondary antibody was removed and the membrane was washed three times with TBST buffer (10 min / time). TCL luminescent liquid A and B were mixed in a ratio of 1:1, and 100 μl was evenly dropped onto the membrane and photographed using a gel imager. The results are shown in Figure 7.
[0272] The results showed that the kit of the present invention, which added agarose microsphere solid phase medium modified with sulfonic acid group ligands, could significantly reduce the production of dsRNA.
[0273] Example 20
[0274] A method for reducing dsRNA formation during in vitro transcription to prepare mRNA, comprising the following steps:
[0275] The method was substantially the same as that described in Comparative Example 1 and Example 9-2, except that the cap analog CAP GAG (3'OMe) was added to the transcription system for co-transcriptional capping, and four 100 μL transcription mixtures were prepared using the green fluorescent protein gene as a template.
[0276] The kit was used in the same manner as described in Comparative Example 1 and Example 9-2, except that the cap analog CAP GAG (3'OMe) was added to the transcription system for co-transcriptional capping, and four 100 μL transcription mixtures were prepared using the green fluorescent protein gene as a template.
[0277] Table 16 shows the transcription systems selected for in vitro transcription. Groups 1-2 and 3-4 in Table 16 differ in whether the modified nucleoside N1-methylpseudouridine (m1ψ) is used; Groups 1 and 2, and Groups 3 and 4 in Table 16, differ in whether a solid phase medium is included in the transcription system.
[0278] Table 16
[0279] Each reaction system was incubated at 37°C for 4 h. After transcription was completed, the transcription mixture and microspheres were separated by centrifugation at 12,000 rpm for 2 min.
[0280] Table 17 compares the statistical results of the relative mRNA yield (%) and the relative dsRNA yield (%) obtained by the co-transcriptional capping system in this example; wherein, the first item in Table 16 of this example (Example 20) is represented by "Example 20-1", the second item in Table 16 of this example (Example 20) is represented by "Example 20-2", and the rest are represented by the same analogy.
[0281] Table 17
[0282] Example 21
[0283] The mRNA obtained in Example 20 was purified using Oligo dT 25 medium and then subjected to a cell transfection experiment. The specific method is as follows:
[0284] Human embryonic kidney 293T cells (HEK293T) were cultured in DMEM medium containing L-glutamine and 10% fetal bovine serum and maintained at 37°C in a humidified incubator with 5% CO2. HEK293T cells were plated at a density of 1-3 × 10 5 Cells were seeded at a density of 100 μg / ml in 24-well black plates and allowed to adhere overnight. Capped mRNA was then added to the cells: 0.5 μg of mRNA, 1 μl of BOOST, and 1 μl of Trans-IT were added sequentially to 50 μl of serum-free medium and mixed thoroughly. The mixture was incubated at room temperature for 2–5 minutes before being added dropwise to the appropriate wells.
[0285] 24 hours after transfection, the expression of EGFP was determined by flow cytometry ( FIG8 ). After transfection, the culture supernatant was collected and the IFN-β protein level was determined by ELISA kit ( FIG9 ).
[0286] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent replacements or improvements made within the spirit and principles of the present application should be included in the scope of protection of the present application.
Claims
1. A method for preparing mRNA with high yield by reducing or inhibiting the formation of double-stranded RNA during in vitro transcription, characterized in that: The preparation method comprises adding a solid phase medium during the transcription process.
2. The mRNA high-yield preparation method according to claim 1, characterized in that: The solid phase medium is a medium modified with negatively charged groups.
3. The mRNA high-yield preparation method according to claim 2, characterized in that: The negatively charged groups modified on the solid phase medium are one or more of sulfonic acid, methylsulfonic acid, ethylsulfonic acid, propylsulfonic acid, phosphate, carboxylic acid, formic acid, hydroxyl, polyadenylic acid, polythymidylic acid, polyuridylic acid, polyguanylic acid and polycytidylic acid.
4. The method for preparing mRNA in high yield according to any one of claims 1 to 3, characterized in that: The solid phase medium is in the form of one or more of granules, films and sheets.
5. The method for preparing mRNA in high yield according to claim 4, characterized in that: The granular solid phase medium includes one or more of microspheres and nanoparticles; The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials; The organic material includes one or more of natural polysaccharides and synthetic polymers; The natural polysaccharide organic material includes one or more of cellulose, dextran, agarose, chitosan and konjac glucomannan; The synthetic polymer includes one or more of styrene polymers, acrylic polymers and polyvinyl acid polymers; The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite; The functional material includes one or more of a magnetic material and a thermosensitive material; The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane; The sheet-like solid phase medium includes carbon nanotubes.
6. The method for preparing mRNA in high yield according to claim 5, characterized in that: The following steps are involved: S1. Pretreatment of the solid phase medium: After washing the solid phase medium with sterile enzyme-free water, balance it with a buffer, shake it for balance and then drain it; preferably, the buffer comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer and HEPES buffer; the shaking balance time is 5-240 min; S2. Prepare an mRNA in vitro transcription system, and add a solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA; the solid phase medium is added to the transcription system mixture at the transcription initiation stage, the transcription process stage or the post-transcription stage, preferably at the transcription initiation stage; the amount of the solid phase medium added is 1-1000 mg / ml, preferably 10-200 mg / ml; the transcription system mixture includes a reaction buffer, a DNA template, NTP, T7 polymerase, an RNase A inhibitor and a pyrophosphatase; the transcription reaction temperature is 20-60°C; S3. After transcription is completed, the supernatant is collected by centrifugation or gravity sedimentation to obtain an mRNA solution; the centrifugation speed is 8000-12000 rpm / min, preferably 10000 rpm / min; the centrifugation time is 1-3 min, preferably 2 min.
7. A kit for in vitro transcription and synthesis of mRNA that can reduce or inhibit the formation of dsRNA, characterized in that: The kit adopts a high-yield mRNA preparation method for reducing or inhibiting the formation of double-stranded ribonucleic acid during in vitro transcription as described in any one of claims 1 to 6, and the kit includes a solid phase medium, a medium balance solution / buffer, a transcription reaction solution, a positive control DNA, NTP, T7 polymerase, an RNase A inhibitor, sterile enzyme-free water and pyrophosphatase.
8. The kit according to claim 7, characterized in that The solid phase medium is a medium modified with negative charge groups; the negative charge groups include one or more of sulfonic acid, methylsulfonic acid, ethylsulfonic acid, propylsulfonic acid, phosphate, carboxylic acid, formic acid, hydroxyl, polyadenylic acid, polythymidylic acid, polyuridylic acid, polyguanylic acid and polycytidylic acid; The solid phase medium is in the form of one or more of granules, films and sheets; The granular solid phase medium includes one or more of microspheres and nanoparticles; The material of the granular solid phase medium includes one or more of organic materials, inorganic materials and functional materials; The organic material includes one or more of natural polysaccharides and synthetic polymers; The natural polysaccharide organic material includes one or more of cellulose, dextran, agarose, chitosan and konjac glucomannan; The synthetic polymer includes one or more of styrene polymers, acrylic polymers and polyvinyl acid polymers; The inorganic material includes one or more of silica gel, glass, metal oxide and hydroxyapatite; The functional material includes one or more of a magnetic material and a thermosensitive material; The membrane solid phase medium includes one or more of nitrocellulose membrane, nylon membrane, and glass cellulose membrane; The sheet-like solid phase medium includes carbon nanotubes; The medium balancing solution / buffer comprises one or more of Tris-HCl buffer, citrate buffer, acetate buffer, phosphate buffer and HEPES buffer; The transcription reaction solution comprises a basic buffer, an inorganic salt and a reducing agent; the basic buffer comprises one or more of a Tris-HCl buffer, a citrate buffer, an acetate buffer, a phosphate buffer and a HEPES buffer; the inorganic salt comprises one or more of NaCl, KCl, MgCl2, Na2SO4, K2SO4 and MgSO4; the reducing agent comprises one or more of DTT, mercaptoethanol and reduced glutathione.
9. The method for using the kit according to claim 8, characterized in that: The following steps are involved: T1. Take the solid phase medium in the kit and perform pretreatment. The pretreatment is to wash the solid phase medium with sterile enzyme-free water and then balance it with medium balance solution; T2. Prepare an mRNA in vitro transcription system using the preparation in the kit, and add the pretreated solid phase medium to the transcription system mixture to perform a transcription reaction to prepare mRNA; T3. After transcription is completed, collect the supernatant by centrifugation or gravity sedimentation to obtain the mRNA solution.
10. The method for using the kit according to claim 9, characterized in that: In the step T1, the pretreatment is to wash the solid phase medium with sterile enzyme-free water, then balance it with a medium balance solution, and then drain it after shaking balance; the shaking balance time is 5-240min; in the step T2, the timing of adding the pretreated solid phase medium to the transcription system mixture is the transcription start stage, the transcription process stage or the post-transcription stage, preferably the transcription start stage; the amount of the solid phase medium added is 1-1000mg / ml, preferably 10-200mg / ml; the transcription system mixture includes a transcription reaction solution, a DNA template, NTP, T7 polymerase, an RNase A inhibitor and a pyrophosphatase; and the transcription reaction temperature is 20-60°C.
Citation Information
Patent Citations
Chaotropic agent for reducing double-stranded RNA formation
CN115087456A
Kit for in vitro transcription synthesis of mRNA capable of reducing or inhibiting dsRNA formation and use method thereof
CN116536306A
High-yield preparation method of mRNA (messenger ribonucleic acid) capable of reducing or inhibiting formation of double-stranded ribonucleic acid in in-vitro transcription process
CN116536307A
Analysis of mRNA heterogeneity and stability
US20160017313A1
Methods for Providing Single-Stranded RNA
US20190153425A1
